tive serum had Gly m 5-and Gly m 6-specific IgE which correlated with positive soy ImmunoCAP. Conclusions: Soy sensitization detected by SPT and Gly m 4 ImmunoCAP were in good qualitative agreement with ISAC results. Soy Immuno-CAP was only specific for Gly m 5 and Gly m 6 sensitization. Gly m 4 ImmunoCAP has a higher sensitivity than Immuno-CAP ISAC. In this patient cohort, Gly m 4 sensitization was linked to the development of severe and generalized allergic reactions upon soy consumption.
patients, Gly m 4 (Bet v 1 homologue) is considered as an allergen linked to crossreactivity and potentially severe symptoms [2] [3] [4] .
The aim of the current study was to apply the allergen microarray diagnosis in a cohort of soy-allergic patients and to compare it to conventional in vitro and in vivo diagnosis.
Methods
Twenty patients (10 males/10 females) from a BP environment with reported soy allergy, ranging in age from 10-69 years (median: 36 years), were enrolled in the study ( table 1 ) . Skin prick tests (SPT) were performed with commercial BP extract (ALK-Abello, Linz, Austria) and with fresh soy drink (Alpro Soja; Alpro, Gent, Belgium). The sera were screened for total IgE and specific IgE for BP, soy, Bet v 1 and Gly m 4 by ImmunoCAP (Phadia AB, Uppsala, Sweden). In addition, 30 ml of each serum sample were analyzed by an allergen microarray (ImmunoCAP ISAC 112; Phadia AB) according to the manufacturer's instructions. GraphPad Pris (version 4.0) was used for statistics and graphs (GraphPad Software Inc., La Jolla, Calif., USA). The nonparametric Spearman correlation coefficient (r) and coefficient of determination (r 2 ) were used to compare the Gly m 4-specific values obtained by the two testing systems.
Results
All patients displayed food-allergic symptoms upon ingestion of soy drinks. In addition, 1 patient had symptoms with cooked soy beans. Nineteen of those were BP allergic (positive SPT and/or CAP results for BP extract and Bet v 1; table 1 ). Thirty percent of the patients (6/20) displayed rather mild symptoms (oral allergy syndrome, OAS) whereas 70% had generalized symptoms ( table 1 ) . Twenty-five percent (5/20) of the patients had no problems with other plant foods and 75% (15/20) had OAS to a range of fruits, primarily apples and other Rosaceae fruits, vegetables and nuts. Severe symptoms occurred in 2 patients upon ingestion of celery and carrot, respectively (data not shown). Eighteen soy-allergic patients were tested positive for soy drink in SPT. CAP results for soy-specific IgE were negative in the majority of tests (15/20) whereas 19/20 sera had specific IgE to Gly m 4.
In the microarray approach, 14/20 sera displayed Gly m 4-specific IgE levels, and the remaining 6 sera had IgE levels below 0.3 ISAC standardized units (ISU; table 1 ) .
Furthermore, all serum samples showed specific IgE antibodies to related food allergens, Cor a 1.04, Mal d 1, Pru p 1, Ara h 8, Act d 8 and Api g 1, with varying concentrations ( fig. 1 a) . In contrast, serum from patient No. 19 without BP allergy had detectable IgE levels to Gly m 5 and Gly m 6 in the ImmunoCAP ISAC, which correlated with positive soy ImmunoCAP results, whereas IgE levels to Bet v 1 and Bet v 1-related food allergens were below the threshold level ( table 1 ) . Additionally, this serum exhibited IgE antibodies to Ara h 1, Ara h 2 and Ara h 3, Cor a 9 as well as Cor a 8, Ara h 9, Jug r 3 and Pru p 3 (data not shown).
There was a strong correlation (r = 0.95, p ! 0.0001) between the Gly m 4 results measured by ImmunoCAP and ImmunoCAP ISAC ( fig. 2 ) .
Regarding ISU values to Gly m 4 and related food allergens, differences were observed ( fig 1 a) . In the microarray analysis, the highest values were measured with Bet v 1, ranging from 0.3 to 94.5 ISU (median 24.9). Specific IgE levels to Cor a 1 ranged from 0.2 to 62.7 ISU (median 9.9), followed by Mal d 1-specific ISU values between 0.1 and 67.9 ISU (median 6.5) and Pru p 1 with values from 1.1 to 51 ISU. In contrast, Gly m 4 levels ranged from 0.1 to 13 ISU (median 1.2) and Api g 1-specific ISU values from 0.2 to 10.6 ISU (median 1.1). However, no association between severity of allergic symptoms and increasing specific IgE levels could be observed for Gly m 4 ( fig. 1 b) . Reversely, specific Mal d 1 levels were generally higher compared to Gly m 4 levels ( fig. 1 b) . Again, no significant association (p 1 0.05) between IgE levels and presence of symptoms (OAS vs. no symptoms) was observed.
Discussion
Taken together, in our patient cohort, SPT with soy drink and Gly m 4 ImmunoCAP proved highly reliable to detect Gly m 4 sensitization. Soy extract ImmunoCAP was highly specific for Gly m 5 and Gly m 6, whereas Gly m 4-specific IgE was neglected by this reagent. Furthermore, sensitization to Gly m 4, the Bet v 1 homologous allergen, tends to induce moderate to rather severe foodallergic symptoms compared to other Bet v 1-related food allergens, such as Mal d 1 [2, 5] . When performing the allergen microarray analysis, there was a highly significant correlation of quantitative results with the Gly m 4 ImmunoCAP ( fig. 2 ) . However, differences around the threshold level were detectable, demonstrating that Gly m 4 ImmunoCAP has a higher sensitivity (95%) than ImmunoCAP ISAC (70%), resulting in a lower quantitative agreement with a cutoff of 0.1 kUA/l for ImmunoCAP and of 0.3 ISU for ImmunoCAP ISAC. 
